INMBInmune Bio, Inc.同业对比
Inmune Bio, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INMB本股 | $65M#8 | — | 3.2x#7 | 1307.2x#7 | 257.1%#2 | -9.5%#5 | -94766.0%#7 | -225.9%#8 | -607.3%#2 | — | 19.5%#4 | — |
| BSEM | $90M#2 | — | 3.3x#8 | — | — | — | — | 0.0%#2 | — | — | — | — |
| PTHS | $88M#3 | — | — | 5.2x#3 | — | -444.6%#14 | -193.1%#3 | — | — | — | -27.3%#8 | — |
| SCTX | $651M#1 | — | — | — | — | — | — | — | — | — | — | — |
| VXRT | $80M#4 | 2.0x#1 | 1.0x#3 | 0.3x#1 | 726.7%#1 | 124.4%#1 | 7.6%#1 | 0.0%#1 | 22.5%#1 | — | -24.0%#7 | — |
| CSBR | $76M#5 | — | 19.6x#10 | 1.3x#2 | 4.4%#3 | -125.0%#13 | -1.9%#2 | -0.0%#3 | — | — | -16.1%#5 | — |
| KLRS | $73M#6 | — | 1.3x#4 | 441.5x#5 | — | 37.2%#2 | -27970.9%#6 | -75.3%#7 | — | — | -30.8%#9 | — |
| ELOX | $72M#7 | 5.0x#2 | 1.6x#5 | — | -100.0%#5 | -90.7%#11 | — | -12.9%#4 | — | — | — | — |
| LONA | $65M#9 | — | 1.9x#6 | — | — | -9.3%#4 | — | -315.5%#10 | — | — | 79.6%#3 | — |
| EXOZ | $62M#10 | — | 17.0x#9 | 887.5x#6 | — | -56.3%#10 | -13867.0%#5 | -250.6%#9 | — | — | -44.1%#11 | — |
| INKT | $59M#11 | — | — | — | — | -15.9%#6 | — | — | — | — | -19.0%#6 | — |
| IMA | $58M#12 | — | 0.4x#1 | 72.6x#4 | -77.1%#4 | -24.0%#7 | -6056.4%#4 | -31.9%#5 | — | — | -39.7%#10 | — |
| BKHAU | $53M#13 | — | — | — | — | -30.6%#8 | — | — | — | — | 133.8%#1 | 96.2%#2 |
| TVGN | $50M#14 | — | — | — | — | -91.4%#12 | — | — | — | — | -81.7%#13 | — |
| BKHA | $49M#15 | — | — | — | — | -30.6%#8 | — | — | — | — | 126.3%#2 | 104.1%#1 |
| TIL | $49M#16 | — | 0.5x#2 | — | -100.0%#5 | 3.7%#3 | — | -66.5%#6 | — | — | -66.5%#12 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议